Anti-CD20 as the B-cell targeting agent in a combined therapy to modulate anti-factor VIII immune responses in hemophilia A inhibitor mice

Chao Lien Liu, Peiqing Ye, Jacqueline Lin, Chérie L. Butts, Carol H. Miao

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Neutralizing antibody formation against transgene products can represent a major complication following gene therapy with treatment of genetic diseases, such as hemophilia A. Although successful approaches have been developed to prevent the formation of anti-factor VIII (FVIII) antibodies, innovative strategies to overcome pre-existing anti-FVIII immune responses in FVIII-primed subjects are still lacking. Anti-FVIII neutralizing antibodies circulate for long periods in part due to persistence of memory B-cells. Anti-CD20 targets a variety of B-cells (pre-B-cells to mature/memory cells); therefore, we investigated the impact of B-cell depletion on anti-FVIII immune responses in hemophilia A mice using anti-CD20 combined with regulatory T (Treg) cell expansion using IL-2/IL-2mAb complexes plus rapamycin. We found that anti-CD20 alone can partially modulate anti-FVIII immune responses in both unprimed and FVIII-primed hemophilia A mice. Moreover, in mice treated with anti-CD20+IL-2/IL-2mAb complexes+rapamycin+FVIII, anti-FVIII antibody titers were significantly reduced in comparison to mice treated with regimens targeting only B or T cells. In addition, titers remained low after a second challenge with FVIII plasmid. Treg cells and activation markers were transiently and significantly increased in the groups treated with IL-2/IL-2mAb complexes; however, significant B-cell depletion was obtained in anti-CD20-treated groups. Importantly, both FVIII-specific antibody-secreting cells and memory B-cells were significantly reduced in mice treated with combination therapy. This study demonstrates that a combination regimen is highly promising as a treatment option for modulating anti-FVIII antibodies and facilitating induction of long-term tolerance to FVIII in hemophilia A mice.

Original languageEnglish
Article number502
JournalFrontiers in Immunology
Volume4
Issue numberJAN
DOIs
Publication statusPublished - 2014

Fingerprint

Factor VIII
Hemophilia A
B-Lymphocytes
Therapeutics
Regulatory T-Lymphocytes
Interleukin-2
Sirolimus
Neutralizing Antibodies
Antibodies
Antibody-Producing Cells
Inborn Genetic Diseases
B-Lymphoid Precursor Cells
Transgenes
Genetic Therapy
Antibody Formation
Plasmids

Keywords

  • Anti-CD20
  • B-cell depletion
  • Factor VIII
  • Hemophilia
  • Immunomodulation
  • Tolerance induction

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Anti-CD20 as the B-cell targeting agent in a combined therapy to modulate anti-factor VIII immune responses in hemophilia A inhibitor mice. / Liu, Chao Lien; Ye, Peiqing; Lin, Jacqueline; Butts, Chérie L.; Miao, Carol H.

In: Frontiers in Immunology, Vol. 4, No. JAN, 502, 2014.

Research output: Contribution to journalArticle

@article{bc2d8fd29c374ebfadace7462ae885eb,
title = "Anti-CD20 as the B-cell targeting agent in a combined therapy to modulate anti-factor VIII immune responses in hemophilia A inhibitor mice",
abstract = "Neutralizing antibody formation against transgene products can represent a major complication following gene therapy with treatment of genetic diseases, such as hemophilia A. Although successful approaches have been developed to prevent the formation of anti-factor VIII (FVIII) antibodies, innovative strategies to overcome pre-existing anti-FVIII immune responses in FVIII-primed subjects are still lacking. Anti-FVIII neutralizing antibodies circulate for long periods in part due to persistence of memory B-cells. Anti-CD20 targets a variety of B-cells (pre-B-cells to mature/memory cells); therefore, we investigated the impact of B-cell depletion on anti-FVIII immune responses in hemophilia A mice using anti-CD20 combined with regulatory T (Treg) cell expansion using IL-2/IL-2mAb complexes plus rapamycin. We found that anti-CD20 alone can partially modulate anti-FVIII immune responses in both unprimed and FVIII-primed hemophilia A mice. Moreover, in mice treated with anti-CD20+IL-2/IL-2mAb complexes+rapamycin+FVIII, anti-FVIII antibody titers were significantly reduced in comparison to mice treated with regimens targeting only B or T cells. In addition, titers remained low after a second challenge with FVIII plasmid. Treg cells and activation markers were transiently and significantly increased in the groups treated with IL-2/IL-2mAb complexes; however, significant B-cell depletion was obtained in anti-CD20-treated groups. Importantly, both FVIII-specific antibody-secreting cells and memory B-cells were significantly reduced in mice treated with combination therapy. This study demonstrates that a combination regimen is highly promising as a treatment option for modulating anti-FVIII antibodies and facilitating induction of long-term tolerance to FVIII in hemophilia A mice.",
keywords = "Anti-CD20, B-cell depletion, Factor VIII, Hemophilia, Immunomodulation, Tolerance induction",
author = "Liu, {Chao Lien} and Peiqing Ye and Jacqueline Lin and Butts, {Ch{\'e}rie L.} and Miao, {Carol H.}",
year = "2014",
doi = "10.3389/fimmu.2013.00502",
language = "English",
volume = "4",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "JAN",

}

TY - JOUR

T1 - Anti-CD20 as the B-cell targeting agent in a combined therapy to modulate anti-factor VIII immune responses in hemophilia A inhibitor mice

AU - Liu, Chao Lien

AU - Ye, Peiqing

AU - Lin, Jacqueline

AU - Butts, Chérie L.

AU - Miao, Carol H.

PY - 2014

Y1 - 2014

N2 - Neutralizing antibody formation against transgene products can represent a major complication following gene therapy with treatment of genetic diseases, such as hemophilia A. Although successful approaches have been developed to prevent the formation of anti-factor VIII (FVIII) antibodies, innovative strategies to overcome pre-existing anti-FVIII immune responses in FVIII-primed subjects are still lacking. Anti-FVIII neutralizing antibodies circulate for long periods in part due to persistence of memory B-cells. Anti-CD20 targets a variety of B-cells (pre-B-cells to mature/memory cells); therefore, we investigated the impact of B-cell depletion on anti-FVIII immune responses in hemophilia A mice using anti-CD20 combined with regulatory T (Treg) cell expansion using IL-2/IL-2mAb complexes plus rapamycin. We found that anti-CD20 alone can partially modulate anti-FVIII immune responses in both unprimed and FVIII-primed hemophilia A mice. Moreover, in mice treated with anti-CD20+IL-2/IL-2mAb complexes+rapamycin+FVIII, anti-FVIII antibody titers were significantly reduced in comparison to mice treated with regimens targeting only B or T cells. In addition, titers remained low after a second challenge with FVIII plasmid. Treg cells and activation markers were transiently and significantly increased in the groups treated with IL-2/IL-2mAb complexes; however, significant B-cell depletion was obtained in anti-CD20-treated groups. Importantly, both FVIII-specific antibody-secreting cells and memory B-cells were significantly reduced in mice treated with combination therapy. This study demonstrates that a combination regimen is highly promising as a treatment option for modulating anti-FVIII antibodies and facilitating induction of long-term tolerance to FVIII in hemophilia A mice.

AB - Neutralizing antibody formation against transgene products can represent a major complication following gene therapy with treatment of genetic diseases, such as hemophilia A. Although successful approaches have been developed to prevent the formation of anti-factor VIII (FVIII) antibodies, innovative strategies to overcome pre-existing anti-FVIII immune responses in FVIII-primed subjects are still lacking. Anti-FVIII neutralizing antibodies circulate for long periods in part due to persistence of memory B-cells. Anti-CD20 targets a variety of B-cells (pre-B-cells to mature/memory cells); therefore, we investigated the impact of B-cell depletion on anti-FVIII immune responses in hemophilia A mice using anti-CD20 combined with regulatory T (Treg) cell expansion using IL-2/IL-2mAb complexes plus rapamycin. We found that anti-CD20 alone can partially modulate anti-FVIII immune responses in both unprimed and FVIII-primed hemophilia A mice. Moreover, in mice treated with anti-CD20+IL-2/IL-2mAb complexes+rapamycin+FVIII, anti-FVIII antibody titers were significantly reduced in comparison to mice treated with regimens targeting only B or T cells. In addition, titers remained low after a second challenge with FVIII plasmid. Treg cells and activation markers were transiently and significantly increased in the groups treated with IL-2/IL-2mAb complexes; however, significant B-cell depletion was obtained in anti-CD20-treated groups. Importantly, both FVIII-specific antibody-secreting cells and memory B-cells were significantly reduced in mice treated with combination therapy. This study demonstrates that a combination regimen is highly promising as a treatment option for modulating anti-FVIII antibodies and facilitating induction of long-term tolerance to FVIII in hemophilia A mice.

KW - Anti-CD20

KW - B-cell depletion

KW - Factor VIII

KW - Hemophilia

KW - Immunomodulation

KW - Tolerance induction

UR - http://www.scopus.com/inward/record.url?scp=84987781475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987781475&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2013.00502

DO - 10.3389/fimmu.2013.00502

M3 - Article

AN - SCOPUS:84987781475

VL - 4

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - JAN

M1 - 502

ER -